We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ad26.COV2-S

News List

Aspen Pharmacare to manufacture Covid-19 vaccine candidate with J&J pharmaceutical-technology
November 05, 2020
Aspen’s South African subsidiary Aspen Pharmacare has signed a preliminary agreement with two Johnson & Johnson (J&J) subsidiaries for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate.
J&J Accelerates COVID-19 Vaccine Candidate americanpharmaceuticalreview
June 22, 2020
Johnson & Johnson announced through Janssen Pharmaceutical, it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July worldpharmanews
June 11, 2020
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.